Page results
-
UCLH provides an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia. We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia.
-
Mindfulness patient information.
-
The bone marrow transplant and haematopoietic stem cell transplant service at UCLH is the largest in Europe and provides a full range of transplant services.
-
This page is for patients having planned neurosurgery.
-
UCLH is a designated Haemophilia Centre providing a 24/7 service for patients, including those needing treatment with blood products and clotting factor medications.
-
Thalassaemia is a group of inherited blood conditions where the part of the blood known as haemoglobin is abnormal.
-
The COVID Medicines Delivery Unit (CMDU gives new COVID-19 treatments for patients at highest risk in the community from the NCL sector. These treatments involve intravenous infustion of neutralising monoclonal antibodies (nMABs) or oral antiviral treatments, which are given to high-risk patients who have had a positive PCR test.
File results
-
FOI/2023/0294 - Patient entertainment
-
FOI/2023/0295 - Strikes and Trust use of the BMA rate card
-
FOI/2023/0296 - Consultant workforce information
-
FOI/2023/0300 - Post-mortem examinations for 2019, 2020, 2021 and 2022
-
FOI/2023/0301 - Meat served at the Trust that may contain nitrates or nitrites
-
FOI/2023/0303 - Sexual harassment from patients towards staff in 2022
-
FOI/2023/0304 - Chronic lymphocytic leukaemia treatments
-
FOI/2023/0308 - Treatment for biologic and biosimilar products within rheumatology
-
FOI/2023/0310 - Biologic treatment/ medicines in dermatology
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide